#China #Shanghai #Stanford Medicine #Idiopathic Pulmonary Fibrosis #Simcere Pharmaceutical

Introduction

On May 29, 2026, Simcere Pharmaceutical Group Limited (2096.HK) announced a significant research collaboration with Stanford Medicine. This partnership aims to accelerate the development of innovative therapies for patients battling idiopathic pulmonary fibrosis (IPF), a progressive lung disease that poses severe health challenges.

The Collaboration

Under this newly inked agreement, Simcere will finance exploratory research focused on a unique molecule aimed at treating IPF. Once the exploration phase is successfully completed, Simcere will license this molecule, acquiring full global rights to the resulting product. The research will leverage the expertise of leading laboratories in chemical biology at Stanford Medicine, guided by renowned scientists Dr. Chaitan Khosla and Dr. Cui Bianxiao from the Stanford Innovative Medicines Accelerator.

Dr. Khosla, a professor in Chemistry and Chemical Engineering, also serves as the director of the Innovative Medicines Accelerator. His credentials include memberships in prestigious scientific academies, marking him as a significant figure in the drive to advance chemical biology applications. Dr. Bianxiao, likewise, is a leading expert in fibrosis, holding accolades like the Barany Award and the NIH New Innovator Award.

Understanding Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis is a chronic, progressive lung disease characterized by unknown causes resulting in the thickening and scarring of lung tissue. This condition ultimately leads to severe breathing difficulties and, unfortunately, lung failure. Current medical treatments have not proven effective in reversing lung fibrosis; thus, the median survival rate post-diagnosis averages only three years, with a mere 20-40% surviving after five years.

Vision and Commitment

Zhou Gaobo, head of investments at Simcere Pharmaceutical, emphasized the importance of this initiative, noting that it represents the second distinctive project fostered through the Simcere-Stanford collaboration. This ongoing partnership signifies a proactive pursuit of “Innovation 2.0” in line with Simcere's mission: “For patients, for life.” The commitment to such groundbreaking work aims to develop further innovative products to directly benefit patients.

In Dr. Khosla's words, there has been a long-standing unmet clinical need for specific therapies targeting idiopathic pulmonary fibrosis. He expressed excitement towards the collaboration with Simcere to implement groundbreaking insights from chemical biology to bridge this gap.

About Simcere Pharmaceutical

Simcere Pharmaceutical (2096.HK) focuses on creating innovative and research-driven pharmaceutical solutions. The company has established a National Key Laboratory dedicated to developing medications in neurology and oncology. Simcere deliberately drives initiatives towards areas with substantial unmet clinical needs, aligned with its mission to benefit patient lives. The combination of proprietary R&D and cooperative innovation, alongside strategic partnerships with various other entities, underscores Simcere's drive to lead in pharmaceutical advancements. For further information, visit www.simcere.com.